We are monitoring the impact of COVID-19 & Recession alarm on Europe Antibody Drug Conjugates Market Get in touch with us for detailed analysis Know More

Know More

Share on

Europe Antibody Drug Conjugates Market Research Report - Segmented By pipeline, Technology, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Size, Share, Trends, Growth, Forecast | 2022 to 2027

Published: January, 2022
ID: 5796
Pages: 145

Europe Antibody Drug Conjugates Market Size & Growth (2022 to 2027):

As Per the Report, the Size of the Europe Antibody Drug Conjugates Market is valued at USD 3.09 billion in 2022 and estimated to be growing at a CAGR of 25.12%, to reach USD 9.48 billion by 2027 during the forecast period 2022 to 2027.

Factors such as sedentary lifestyles and the growing number of people who smoke and drink regularly have increased the prevalence of cancer worldwide. The Europe antibody drug conjugates market is increasing owing to the increased research activity on antibody therapies, preclinical research, high research on breakthrough drug discoveries and growing demand for cost-effective and effective cancer treatments, increased research on cancerous diseases, as well as collaboration Increased between research institutes, biotechnology companies, and biopharmaceuticals industries. Antibody drug conjugates help optimize existing chemical triggers and develop new chemical triggers to generate highly selective linkers in the body. They also create novel linker-antibody couplings to produce stable and homogeneous antibody drug conjugates. In addition, they focus on improving absorption, distribution, metabolism, and excretion, which creates a favorable market outlook.

Currently, 11 FDA-approved conjugates are expected to generate more than $ 22 billion in sales per year by 2030. Due to the increasing incidence of cancer around the globe, these numbers are expected to rise. According to Globocan, cancer incidence reached 19.5 million, and the estimated cancer deaths were 9.97 million. The incidence will reach 22 million by 2025 and 26.7 million by 2030. There are around 378,000 new cancer cases in the UK every year, or 1,000 per day. The National Cancer Institute estimates that cancer diagnosis is extrapolated to approximately 15 million by 2024. Therefore, these factors could generate positive growth for the European antibody drug conjugate market during the evaluation period.

In addition, the high healthcare expenditure in European countries provides the market with an opportunity to grow during the forecast period with better treatment modalities for cancer patients in this region. Furthermore, advancements in antibody drug conjugates cross-link technology to identify and kill disease-associated cells, further stimulating the growth of ADC development in this region.

However, several factors such as the high cost of procedures and lack of funds, the lower success rate in manufacturing antibody conjugates, and strict government rules will restrain the market growth during 2020-2025. These drugs respond person to person and may not be successful in all cases, affecting patient compliance and healthcare insurance policies. Most European countries lack the required reimbursement laws for the desired cancer treatment, thus delaying the adoption of these antibody-based drug conjugates. Most cancer treatments require long-term drug usage for a better prognosis. All these factors are anticipated to reduce the growth of the European antibody drug conjugates market.

This research report on the Europe Antibody Drug Conjugates Market has been segmented and sub-segmented into the following categories 

By pipeline:

  • Phase
  • Mode of action
    • Igg1 antibodies
    • HER2 antibodies
  • Technology, linker.

By Technology:

  • Seattle genetics
  • Immunogen
  • Immunomedics

By End User:

  • Research institutes
  • Hospitals
  • Clinics

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the Germany Antibody Drug Conjugates Market is expected to witness immense growth at a CAGR of 5.5% during the forecast period 2020-2025. The increasing incidence of cancer in the region may invite promising development. Moreover, factors such as growing awareness among the population, increasing health infrastructure, and early cancer screening initiatives will drive the market in this region.

The United Kingdom Antibody Drug Conjugates Market is expected to have the second-largest market share in the European antibody-drug conjugate market. This regional market is expected to experience substantial growth due to the increase in government initiatives and significant biopharmaceutical companies in the region.

The France Antibody Drug Conjugates Market also held a dominant share in terms of revenue in 2020, with a market share of 21.2% in the forecast period 2020-2025. This regional market is expected to show moderate growth, attributed to the availability of key players, high population growth, and increase of different types of cancers, more universities, and research centers focused on antibody and drug conjugates.

KEY MARKET PLAYERS

Prominent Companies dominating the Europe Antibody Drug Conjugates Market Profiled in the Report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.,

1. Introduction        

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                  

                2.1 Introduction      

                2.2 Research Phases                      

       2.2.1 Secondary Research           

       2.2.2 Primary Research 

       2.2.3 Econometric Modelling      

       2.2.4 Expert Validation  

                2.3 Analysis Design

                2.4 Study Timeline 

3. Overview              

                3.1 Executive Summary                

                3.2 Key Inferences

                3.3 Epidemiology     

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)           

                4.1 Market Drivers 

                4.2 Market Restraints                    

                4.3 Key Challenges

                4.4 Current Opportunities in the Market     

5. Market Segmentation                     

                5.1 Pipeline Analysis                      

       5.1.1 Introduction           

       5.1.2 Phase        

       5.1.3  Mode of action    

                       5.1.3.1 IgG1 antibodies

                       5.1.3.2 HER2 antibodies

       5.1.4 Technology             

                       5.1.4.1 Seattle Genetics

                       5.1.4.2 Immunogen

                       5.1.4.3 Immunomedics

       5.1.5 Linker        

       5.1.6 Y-o-Y Growth Analysis, By Pipeline Analysis              

       5.1.7 Market Attractiveness Analysis, By Pipeline Analysis            

       5.1.8 Market Share Analysis, By Pipeline Analysis             

                5.2 End-user                      

       5.2.1 Introduction           

       5.2.2 Research institutes              

       5.2.3 Hospitals  

       5.2.4 Clinics        

       5.2.5 Others      

       5.2.6 Y-o-Y Growth Analysis, By End-user             

       5.2.7 Market Attractiveness Analysis, By End-user           

       5.2.8 Market Share Analysis, By End-user             

6. Geographical Analysis                     

                6.1 Introduction      

       6.1.1 Regional Trends    

       6.1.2 Impact Analysis     

       6.1.3 Y-o-Y Growth Analysis        

                       6.1.3.1 By Geographical Area

                       6.1.3.2 By Pipeline Analysis

                       6.1.3.3 By End-user

       6.1.4  Market Attractiveness Analysis     

                       6.1.4.1 By Geographical Area

                       6.1.4.2 By Pipeline Analysis

                       6.1.4.3 By End-user

       6.1.5  Market Share Analysis      

                       6.1.5.1 By Geographical Area

                       6.1.5.2 By Pipeline Analysis

                       6.1.5.3 By End-user

                6.2 U.K                 

                6.3 Spain    

                6.4 Germany                     

                6.5 Italy      

                6.6 France 

                6.7 Rest of Europe

7. Strategic Analysis              

                7.1 PESTLE analysis

       7.1.1 Political     

       7.1.2 Economic 

       7.1.3 Social         

       7.1.4 Technological         

       7.1.5 Legal          

       7.1.6 Environmental       

                7.2 Porter’s Five analysis     

       7.2.1 Bargaining Power of Suppliers        

       7.2.2 Bargaining Power of Consumers    

       7.2.3 Threat of New Entrants     

       7.2.4 Threat of Substitute Products and Services              

       7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis               

                8.1 Seattle Genetics                       

       8.1.1 Overview 

       8.1.2 Product Analysis   

       8.1.3 Financial analysis  

       8.1.4 Recent Developments       

       8.1.5 SWOT analysis       

       8.1.6 Analyst View          

                8.2 Genentech                 

                8.3 Takeda Pharmaceuticals                       

                8.4 F. Hoffmann-La Roche  

                8.5 Bayer Healthcare                     

                8.6 Agensys, Inc.,   

                8.7 Immunogen      

                8.8 Novartis                       

                8.9 Oxford Biotherapeutics

                8.10 Synthon Biopharmaceuticals   

9. Competitive Landscape                  

                9.1 Market share analysis   

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, Collaborations, and Joint Ventures

                9.4 New Product Launches

10. Market Outlook and Investment Opportunities                

Appendix                  

                a) List of Tables                

                b) List of Figures     

  1. Europe Antibody Drug Conjugates  Market By Pipeline Analysis, From 2022 - 2027 ( USD Billion )
  2. Europe Phase Market By Region, From 2022 - 2027 ( USD Billion )
  3. Europe Mode of action Market By Region, From 2022 - 2027 ( USD Billion )
  4. Europe Technology Market By Region, From 2022 - 2027 ( USD Billion )
  5. Europe Linker Market By Region, From 2022 - 2027 ( USD Billion )
  6. Europe Antibody Drug Conjugates  Market By End-user , From 2022 - 2027 ( USD Billion )
  7. Europe Research institutes Market By Region, From 2022 - 2027 ( USD Billion )
  8. Europe Hospitals  Market By Region, From 2022 - 2027 ( USD Billion )
  9. Europe Clinics Market By Region, From 2022 - 2027 ( USD Billion )
  10. Europe Others Market By Region, From 2022 - 2027 ( USD Billion )
  11. U.K. Antibody Drug Conjugates  Market By Pipeline Analysis , From 2022 - 2027 ( USD Billion )
  12. U.K. Antibody Drug Conjugates  Market By End-user , From 2022 - 2027 ( USD Billion )
  13. Germany Antibody Drug Conjugates  Market By Pipeline Analysis , From 2022 - 2027 ( USD Billion )
  14. Germany Antibody Drug Conjugates  Market By End-user , From 2022 - 2027 ( USD Billion )
  15. France Antibody Drug Conjugates  Market By Pipeline Analysis , From 2022 - 2027 ( USD Billion )
  16. France Antibody Drug Conjugates  Market By End-user , From 2022 - 2027 ( USD Billion )
  17. Italy Antibody Drug Conjugates  Market By Pipeline Analysis , From 2022 - 2027 ( USD Billion )
  18. Italy Antibody Drug Conjugates  Market By End-user , From 2022 - 2027 ( USD Billion )
  19. Spain Antibody Drug Conjugates  Market By Pipeline Analysis , From 2022 - 2027 ( USD Billion )
  20. Spain Antibody Drug Conjugates  Market By End-user , From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample